Congress extends ALS research funding, adds safety oversight for rare diseases
H.R. 8205 — Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 · Filed by Mike Quigley (D-IL) · 103 cosponsors · Introduced Apr 6, 2026 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031 and adds new requirements: drug manufacturers must provide enrollment, safety, and efficacy data when seeking grant renewals; grantees must report serious adverse events to the grant-making institution; the FDA must publish an action plan within 18 months describing its 5-year strategy for ALS and other rare neurodegenerative diseases, and report on implementation within 5 years. The bill expands the original ALS-focused program to include other rare neurodegenerative diseases.
Why we flagged it
The bill's core function is to extend and enhance an existing accelerated-access program for ALS therapies, add safety and data-reporting requirements, and expand FDA oversight to include other rare neurodegenerative diseases. It is a straightforward reauthorization with modest procedural improvements.
What the text implies
- Expansion from ALS-only to 'other rare neurodegenerative diseases' may broaden FDA resource demands and set precedent for similar expansions in other disease-specific programs.
- Requirement for manufacturers to provide 'available efficacy data' during grant renewal may create competitive intelligence disclosure obligations that could affect proprietary trial information.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers developing ALS and rare neurodegenerative disease therapies; clinical research institutions and grant recipients; academic medical centers conducting phase 2/3 trials